Stock Track | Revolution Medicines Plunges 7.98% After-Hours on Earnings Miss and $1 Billion Stock Offering Plan

Stock Track02-26

Revolution Medicines, Inc. (RVMD) experienced a significant after-hours plunge of 7.98% on Wednesday, following the release of its fourth-quarter financial results and a new capital-raising plan.

The biotechnology company reported a quarterly loss of $1.86 per share, which was wider than the FactSet consensus estimate for a loss of $1.58 per share. This represents a 66% increase in losses compared to the same period last year. The net loss for the quarter widened to $364.9 million, driven by a substantial rise in research and development expenses, which increased to $294.9 million.

Further pressuring the stock was the company's filing for a common stock offering of up to $1.0 billion, as disclosed in an SEC filing just minutes before the sharp price decline. Investors often react negatively to such offerings due to potential dilution of existing shares. Additionally, the company provided guidance for 2026, expecting GAAP operating expenses to be between $1.6 billion and $1.7 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160968591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 06:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160968591","market":"us","top_or_hot":-1,"title":"Stock Track | Revolution Medicines Plunges 7.98% After-Hours on Earnings Miss and $1 Billion Stock Offering Plan","media":"Stock Track","content":"<p>Revolution Medicines, Inc. (RVMD) experienced a significant after-hours plunge of 7.98% on Wednesday, following the release of its fourth-quarter financial results and a new capital-raising plan.</p><p>The biotechnology company reported a quarterly loss of $1.86 per share, which was wider than the FactSet consensus estimate for a loss of $1.58 per share. This represents a 66% increase in losses compared to the same period last year. The net loss for the quarter widened to $364.9 million, driven by a substantial rise in research and development expenses, which increased to $294.9 million.</p><p>Further pressuring the stock was the company's filing for a common stock offering of up to $1.0 billion, as disclosed in an SEC filing just minutes before the sharp price decline. Investors often react negatively to such offerings due to potential dilution of existing shares. Additionally, the company provided guidance for 2026, expecting GAAP operating expenses to be between $1.6 billion and $1.7 billion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Revolution Medicines Plunges 7.98% After-Hours on Earnings Miss and $1 Billion Stock Offering Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Revolution Medicines Plunges 7.98% After-Hours on Earnings Miss and $1 Billion Stock Offering Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 06:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Revolution Medicines, Inc. (RVMD) experienced a significant after-hours plunge of 7.98% on Wednesday, following the release of its fourth-quarter financial results and a new capital-raising plan.</p><p>The biotechnology company reported a quarterly loss of $1.86 per share, which was wider than the FactSet consensus estimate for a loss of $1.58 per share. This represents a 66% increase in losses compared to the same period last year. The net loss for the quarter widened to $364.9 million, driven by a substantial rise in research and development expenses, which increased to $294.9 million.</p><p>Further pressuring the stock was the company's filing for a common stock offering of up to $1.0 billion, as disclosed in an SEC filing just minutes before the sharp price decline. Investors often react negatively to such offerings due to potential dilution of existing shares. Additionally, the company provided guidance for 2026, expecting GAAP operating expenses to be between $1.6 billion and $1.7 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1160968591","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160968591","pubTimestamp":1772057566,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Revolution Medicines, Inc. (RVMD) experienced a significant after-hours plunge of 7.98% on Wednesday, following the release of its fourth-quarter financial results and a new capital-raising plan.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"个股追踪|Revolution Medicines盘后暴跌7.98%，因盈利不及和10亿美元股票发行计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"Revolution Medicines, Inc. (RVMD) experienced a significant after-hours plunge of 7.98% on Wednesday, following the release of its fourth-quarter financial results and a new capital-raising plan.The biotechnology company reported a quarterly loss of $1.86 per share, which was wider than the FactSet consensus estimate for a loss of $1.58 per share. This represents a 66% increase in losses compared to the same period last year. The net loss for the quarter widened to $364.9 million, driven by a substantial rise in research and development expenses, which increased to $294.9 million.Further pressuring the stock was the company's filing for a common stock offering of up to $1.0 billion, as disclosed in an SEC filing just minutes before the sharp price decline. Investors often react negatively to such offerings due to potential dilution of existing shares. Additionally, the company provided guidance for 2026, expecting GAAP operating expenses to be between $1.6 billion and $1.7 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160968591","isCrawlerRequest":true}